Biomind Labs Secures CAD $2.52 Million Through Private Placement

Biomind Labs Inc., a Toronto-based clinical-stage biopharmaceutical firm, has announced its plan to raise CAD $2.52 million through a non-brokered private placement. The offering includes up to 28 million units, each priced at $0.09, comprising one common share and one purchase warrant. These warrants allow holders to acquire additional shares at $0.12 within two years post-offering.

The closing is scheduled for around February 6, 2026, pending customary conditions and regulatory approvals. Proceeds aim to further Biomind's clinical projects and regulatory setups, along with general capital needs. The offered securities won't be registered under U.S. laws, thus limiting their sale outside Canada.

Biomind specializes in creating novel pharmaceutical solutions, targeting neurological conditions via innovative drug delivery systems. The company's strategy includes adherence to rigorous clinical evaluation and innovation focused on patient needs.